Current Report Filing (8-k)
20 May 2021 - 6:16AM
Edgar (US Regulatory)
0001722964
false
0001722964
2021-05-19
2021-05-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 19, 2021
Y-MABS THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-38650
|
|
47-4619612
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
230 Park Avenue
Suite 3350
New York, New York 10169
(Address of principal executive offices)
(Zip Code)
(646) 885-8505
(Registrant’s telephone number,
include area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol
|
|
Name of each exchange on which registered:
|
Common Stock, $0.0001 par value
|
|
YMAB
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events
On May 19, 2021, Y-mAbs Therapeutics,
Inc., (the “Company”) issued a press release announcing that the Company had entered into an exclusive distribution agreement
with Adium Pharma S.A. to be the exclusive distributor in Latin America of the Company’s antibodies, DANYELZA® (naxitamab-gqgk)
for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric
patients with CNS/leptomeningeal metastasis from neuroblastoma. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished
pursuant to Item 8.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Y-MABS THERAPEUTICS, INC.
|
|
|
|
Date: May 19, 2021
|
By:
|
/s/ Thomas Gad
|
|
|
Thomas Gad
|
|
|
Founder, Chairman, President and Head of Business Development & Strategy
|
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024